Moscow is increasing the production of innovative medicines

Moscow is increasing the volume of production of innovative medicines. In the first 11 months of 2025, drug production increased by 11.8 percent compared to the same period in 2024. Sergei Sobyanin told about this in his channel in the MAX messenger.

"Moscow holds a leading position in the country in terms of the pharmaceutical industry and the number of medicines being marketed. Today, the industry pays special attention to biopharma. The direction opens up new possibilities for the treatment of complex diseases, from oncological and autoimmune pathologies to rare genetic disorders," wrote the Mayor of Moscow.

For example, Technopolis Moscow, a resident of the special economic zone (SEZ), produces biologics used for orphan and socially significant diseases. For example, a biosimilar of the thrombolytic drug "Alteplaza" used in acute myocardial infarction and ischemic stroke.

Medicines for the treatment of oncological and autoimmune diseases, including the first Russian original drug for the treatment of multiple sclerosis, are being produced at the site of another SEZ resident.

Another Moscow—based enterprise, Technopolis Moscow SEZ, creates biological products, including medicines for the treatment of breast cancer, colorectal cancer, non-Hodgkin's lymphoma and rheumatoid arthritis.

One of the capital's factories will present its first monoclonal antibody—based drug, Adalimumab, this year. It is a biological immunosuppressant that is used for more than 10 medical indications. In particular, rheumatoid arthritis, Crohn's disease, Behcet's disease and others.

An effective set of measures is in place to support enterprises, including tax preferences and financial instruments. They also have access to a well-developed industrial infrastructure. One of the largest pharmaceutical clusters in the country has been created in the capital.